Panel Discussion: Assessing the Risk of Insertional Mutagenesis by AAV Gene Therapies

Time: 5:45 pm
day: Day One


This panel will be a structured conversation designed to answer key questions such as:

  • What is the rate of integration of AAV vectors?
  • What is the structure of the integrated viral sequences?
  • Is the risk dependent on dose?
  • What is the role of species differences when looking at preclinical data, will this translate to humans?
  • The need for industry collaboration to share data around risk of mutagenesis